DNM1-related disorder shows phenotypic homogeneity and variant clustering in 95 individuals.
This cohort study assessed the genotypic and phenotypic landscape of DNM1-related disorder, a developmental and epileptic encephalopathy, in a population of 95 individuals sourced from multiple locations. The study compared these cases against other genetic epilepsy conditions involving SCN2A, SCN8A, STXBP1, and SYNGAP1. No specific intervention or exposure was reported, and the setting was not specified.
Analysis of disease-causing variants revealed that they cluster in mutational hotspots within the DNM1 gene. Pathogenicity evidence was classified as strong or moderate based on ACMG guidelines. The overall DNM1 phenotype was found to be homogeneous when compared to the comparator genetic epilepsy conditions.
Specific variant associations were identified. The p.R237W variant (n=15) was associated with bilateral tonic-clonic seizures, infantile spasms, and dystonia. The p.I398_R399insCR variant (n=14) was associated with severe hypotonia, profound global delay, and cortical visual impairment. Homozygous loss-of-function variants presented a clinically similar disorder to the dominant-negative type, but microcephaly and brain MRI abnormalities were more common in this specific group.
Safety data, tolerability, and adverse events were not reported. A key limitation noted was the sparse patient descriptions in the current understanding of the condition. While DNM1 represents an attractive target for targeted therapy development, the evidence is observational and does not establish causality for therapeutic interventions.